ArticleJournal of managed care & specialty pharmacy2019

Budget Impact of Dabrafenib and Trametinib in Combination as Adjuvant Treatment of BRAF V600E/K Mutation-Positive Melanoma from a U.S. Commercial Payer Perspective.

Daniel Stellato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.